Zoliflodacin (ETX0914;AZD0914) 是一种新型的螺旋嘧啶三酮，细菌DNA促旋酶/拓扑异构酶 抑制剂。Zoliflodacin 对革兰氏阳性和阴性生物具有有效的体外抗菌活性，对金黄色葡萄球菌的b>MIC₉₀ 值为0.25 μg/mL。

Zoliflodacin (ETX0914;AZD0914) is a novel spiropyrimidinetrione bacterial DNA gyrase/topoisomerase inhibitor. Zoliflodacin has potent in vitro antibacterial activity against Gram-positive and Gram-negative organisms, including S. aureus with the MIC 90 of 0.25 μg/mL.

Solid

Quinolone

Zoliflodacin has antibacterial activity against key Gram-positive ( Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus pyogenes, and Streptococcus agalactiae ), fastidious Gram-negative ( Haemophilus influenzae, Neisseria gonorrhoeae ), atypical ( Legionella pneumophila ), and anaerobic ( Clostridium difficile ) bacterial species, including isolates with known resistance to fluoroquinolones. The antibacterial activity of Zoliflodacin is shown to be via inhibition of DNA biosynthesis and accumulation of double-strand cleavages; this mechanism of action differs from those of other marketed antibacterial compounds, including fluoroquinolones. Zoliflodacin stabilizes and arrests the cleaved covalent complex of gyrase with double-strand broken DNA under permissive conditions and thus blocks religation of the double-strand

Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years；4°C 2 years

[1]. Huband MD, et al. In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteria. Antimicrob Agents Chemother. 2015 Jan;59(1):467-74.

In Vitro: DMSO : 140 mg/mL (287.21 mM; Need ultrasonic)配制储备液